Cases in TK2d Care: Lessons Learned in Diagnosing and Managing a Rare Disease

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.

Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.

The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.

The diagnosis and management of the rare genetic disease thymidine kinase 2 deficiency (TK2d) can come with many challenges. So to help shed light on those challenges and key management strategies, Dr. Charles Turck speaks with Dr. Bruce Cohen about his experiences and approaches to real-world patient cases in TK2d care. Dr. Cohen is the Chair of the NeuroDevelopmental Science Center at Akron Children’s Hospital in Ohio.

Thymidine kinase 2 deficiency is a very rare disorder that presents several diagnostic and treatment challenges. Learn more about those challenges along with the clinical manifestations of thymidine kinase 2 deficiency and the importance of taking a multidisciplinary approach to care with Dr. Bruce H. Cohen, Chair of the NeuroDevelopmental Science Center at Akron Children’s Hospital.

The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.